Intralink-Spine Inc. (ILS) is a company formed to develop, manufacture, and sell a proprietary, tissue revitalization reagent that can be injected into the spinal disc to mechanically reinforce and stabilize the joint and decompress the surrounding neural tissues without the need for invasive spinal surgery. Our technology, NEXT (Nonsurgical EXogenous crosslink Therapy), is engineered to reduce disc bulge under load and significantly strengthen disc tissue, increasing its durability and tear resistance for immediate and long term treatment of Degenerative Disc Disease (DDD) and its associated pathologies including Spinal Stenosis, Herniated Disks, Post-Surgical Syndromes and Back Pain, affecting over 15 million people each year in the US alone. NEXT is based on the body’s own natural response to repair instability and degradation of the spinal disc. The NEXT device instantly and directly strengthens and stabilizes the disc, reducing the pain of the patient without the costs and risks associated with surgery.
Press Release 2.1.2010: INTRALINK-SPINE INC. AWARDED $750,000 SMALL BUSINESS INNOVATION RESEARCH PHASE II GRANT
Register to download
the Business Strategy PDF